 Esperion is deeply undervalued company selling a new treatment in the huge and lucrative market for lowering LDL cholesterol. ESPR is highly leveraged to Covid-reopening, but unlike many industries, it has gotten no bump from vaccine news. ESPR is financially healthy and will survive and thrive. 